Breaking News Instant updates and real-time market news.

HD

Home Depot

$188.00

-3.15 (-1.65%)

, BA

Boeing

$341.39

-3 (-0.87%)

12:44
05/15/18
05/15
12:44
05/15/18
12:44

On The Fly: Top stock stories at midday

Stocks opened in negative territory, putting the Dow's eight-day win streak in jeopardy. Some of the weakness is attributed to the pressure from Dow component Home Depot (HD), which is falling following its Q1 results. While its shares have recovered slightly, the averages remain under pressure at midday. ECONOMIC EVENTS: In the U.S., retail sales rose 0.3% in April, matching economists' consensus view. The Empire state manufacturing index bounced 4.3 points to 20.1 in May, which was better than expected. Business inventories were flat in March, with sales up 0.5%. A housing index kept by the National Association of Home Builders rose one point to a reading of 70 for May. In Asia, China's retail sales growth of 9.4% fell short of the 10% growth expectation, though industrial production growth of 7% was ahead of expectations. The Eurozone GDP numbers for Q1 were inline w/expectations. In Europe, the second estimate of the EU's statistics agency showed that the eurozone's GDP expanded by 0.4% in the first quarter of the year compared with the previous quarter, in-line with the preliminary estimate. COMPANY NEWS: Shares of Home Depot have slid about 1.5% after softer seasonal sales impacted by weather caused the home improvement giant's revenue to miss expectations in the first quarter. Of note, Home Depot's same-store sales growth of 4.2% in the quarter came in below the company's full-year forecast for same-store sales to rise 5% compared to last year... Boeing (BA) noted that the World Trade Organization issued its final decision in a case brought by the U.S. and the aircraft maker, stating that "the WTO has determined the EU must end its unfair business practices and remedy the ongoing harm caused by the illegal subsidies." Boeing added that the ruling "clears the way for the United States Trade Representative to seek remedies in the form of tariffs against European imports to the United States [that] are likely to total billions in duties per year, unless and until Airbus addresses the illegal subsidies it received from European governments for its most recently launched airplanes." MAJOR MOVERS: Among the noteworthy gainers was Hollysys Automation (HOLI), which rose 13.5% after its Q3 report prompted upgrades of the stock at Citi and JPMorgan. Also higher was Valeant (VRX), which gained 3.5% after Mizuho analyst Irina Koffler upgraded the stock to Buy from Neutral, saying that adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. Among the notable losers was Tesla (TSLA), which slipped 3% after Morgan Stanley analyst Adam Jonas made significant cuts to his near-term and long-term auto margin forecasts and cut his price target on the stock down to $291 from $376. Also lower were Vipshop (VIPS) and Agilent (A), which fell a respective 19% and nearly 9% after reporting quarterly results. INDEXES: Near midday, the Dow was down 212.00, or 0.85%, to 24,687.41, the Nasdaq was down 69.14, or 0.93%, to 7,342.17, and the S&P 500 was down 20.78, or 0.76%, to 2,709.35.

HD

Home Depot

$188.00

-3.15 (-1.65%)

BA

Boeing

$341.39

-3 (-0.87%)

HOLI

Hollysys

$25.22

3.12 (14.12%)

VRX

Valeant

$21.56

0.76 (3.65%)

TSLA

Tesla

$283.21

-8.63 (-2.96%)

VIPS

Vipshop

$12.17

-2.93 (-19.40%)

A

Agilent

$63.33

-5.91 (-8.54%)

  • 15

    May

  • 15

    May

  • 15

    May

  • 15

    May

  • 30

    May

  • 18

    Jun

  • 27

    Aug

HD Home Depot
$188.00

-3.15 (-1.65%)

05/15/18
LOOP
05/15/18
NO CHANGE
Target $187
LOOP
Home Depot reported 'mixed' Q1 'at best,' says Loop Capital
Loop Capital analyst Laura Champine views Home Depot's Q1 report as a "mixed performance, at best." Home Depot's same-store-sales of 4.2% missed the analyst's estimate of 5%, but she notes the weakness was anticipated given weather trends in the quarter. Further, Champine notes the earnings number benefited by 7c on a lower tax rate than she had modeled. Home Depot now has even more riding on its performance in the seasonal peak of Q2, Champine tells investors in a post-earnings research note. She keeps a Hold rating on the shares with a $187 price target.
05/15/18
BARD
05/15/18
NO CHANGE
Target $215
BARD
Outperform
Home Depot weakness a buying opportunity, says Baird
Baird analyst Peter Benedict said softer seasonal sales impacted by weather was the reason for Home Depot's revenue miss in Q1. He said the company is seeing strong momentum thus far in May and 2018 guidance was maintained, so he would be a buyer of any weakness following the quarterly report. Benedict reiterated his Outperform rating and $215 price target on Home Depot shares, which are down about 2.7% to $186 in early pre-market trading.
05/09/18
CLVD
05/09/18
NO CHANGE
CLVD
Home Depot 2018 comp estimate of 6% looks reasonable, says Cleveland Research
Cleveland Research said its Home Depot 2018 comp estimate of 6%, versus guidance of 5%, looks reasonable given solid underlying demand, share gains, and incremental inflation.
05/09/18
CLVD
05/09/18
NO CHANGE
CLVD
Lowe's comp gap versus Home Depot could widen, says Cleveland Research
Cleveland Research said Lowe's (LOW) comp gap versus Home Depot (HD) could widen further given continued disruptions and inefficiencies in execution.
BA Boeing
$341.39

-3 (-0.87%)

04/26/18
FBCO
04/26/18
NO CHANGE
Target $455
FBCO
Outperform
Boeing price target raised to $455 from $443 at Credit Suisse
Credit Suisse analyst Robert Spingarn raised his price target for Boeing to $455 from $443 as he is enthusiastic about both the macro revenue story and the micro margin story, the latter of which is driven by a generational initiative by management to streamline the aircraft production process and the supply chain behind it. The analyst reiterates an Outperform rating on the shares.
05/09/18
BERN
05/09/18
NO CHANGE
BERN
U.S. exiting Iran deal minor negative for Boeing, Airbus, says Bernstein
Bernstein analyst Douglas Harned notes that President Trump announced that the U.S. will withdraw from the 2015 Iran nuclear accord, and will reinstate sanctions on that country. The analyst sees only minimal impact to commercial aerospace as neither Airbus (EADSY) nor Boeing (BA) will change production rates on this change, and the total number of orders affected represents just 2% of the companies' combined order backlogs. For defense contractors with significant Middle Eastern exposure, heightened regional tensions could drive increased demand for missile defense, in particular, but potentially also aircraft, ships, missiles, and vehicles, he contends. Harned believes Raytheon (RTN) is well positioned, having the highest exposure to missile defense and tactical missile sales to the Middle East, with Lockheed Martin (LMT) also a strong player.
04/26/18
04/26/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Buy from Neutral at UBS, to Outperform from Neutral at Macquarie, and to Neutral from Underweight at Atlantic Equities. 2. Boeing (BA) upgraded to Buy from Hold at Societe Generale. 3. Chipotle (CMG) upgraded to Buy from Neutral at BTIG, to Buy from Hold at Canaccord, to Neutral from Sell at Guggenheim, and to Market Perform from Underperform at Cowen. 4. Wex (WEX) upgraded to Buy from Neutral at Citi with analyst Peter Christiansen saying despite rallying 28% in the past six months, the stock should "grind further on continued organic momentum, though importantly on favorable margin dynamics." 5. Anthem (ANTM) upgraded to Overweight from Neutral at JPMorgan with analyst Gary Taylor saying he continues to be comfortable with the near-term trajectory of medical cost trends for the health insurance industry and maintains a long-term preference to own payors over providers. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/18
WELS
04/26/18
NO CHANGE
Target $370
WELS
Market Perform
Boeing price target raised to $370 from $365 at Wells Fargo
Wells Fargo analyst Sam Pearlstein raised his price target for Boeing to $370 from $365 following quarterly results. The analyst reiterates a Market Perform rating on the shares.
HOLI Hollysys
$25.22

3.12 (14.12%)

09/28/17
DBAB
09/28/17
NO CHANGE
Target $25
DBAB
Buy
Hollysys target raised to $25 after management meetings at Deutsche Bank
After hosting non-deal roadshows with management, Deutsche Bank analyst Sky Hong raised Hollysys Automation Technologies' price target to $25 from $23. The shares, despite rebounding 25% from lows over the past three months, still do not reflect the company's "multi-year robust growth," Hong tells investors in a research note partially titled "another leg of re-rating looks well-deserved." The analyst keeps a Buy rating on Hollysys.
02/09/18
JPMS
02/09/18
DOWNGRADE
JPMS
Neutral
Hollysys downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Karen Li downgraded Hollysys Automation Technologies to Neutral following the company's Q2 results.
05/15/18
JPMS
05/15/18
UPGRADE
JPMS
Overweight
Hollysys upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Karen Li upgraded Hollysys Automation Technologies to Overweight citing an acceleration of industrial automation order growth and its expanding factory automation business. Citi this morning also upgraded Hollysys following the company's Q3 results.
05/15/18
SBSH
05/15/18
UPGRADE
SBSH
Buy
Hollysys upgraded to Buy from Neutral at Citi
Citi upgraded Hollysys Automation Technologies to Buy following last night's Q3 results and raised its price target for the shares to $26.30 from $25.90. The firm highlights the company's faster expansion into automation.
VRX Valeant
$21.56

0.76 (3.65%)

05/15/18
05/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Gap (GPS) upgraded to Outperform from Market Perform at Telsey Advisory. 2. CBS (CBS) upgraded to Outperform from Market Perform at Bernstein with the firm saying it views the probability of a CBS-Viacom (VIAB) re-merger as close to zero, for many years to come. 3. Ulta Beauty (ULTA) upgraded to Outperform from Perform at Oppenheimer with analyst Rupesh Parikh saying he still sees the potential for more gains and outperformance from current levels. 4. Valeant (VRX) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying adjusting individual product growth estimates has made her more constructive on Valeant's turnaround story. 5. Scotts Miracle-Gro (SMG) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying he believes the bottom in the stock price has been reached, leading to its usual "counter seasonal trend of outperformance" given that the stock has outperformed the S&P500 from June to January in the past 11 of 15 years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/14/18
BMOC
05/14/18
NO CHANGE
Target $20
BMOC
Market Perform
Valeant price target raised to $20 from $17 at BMO Capital
BMO Capital analyst Gary Nachman raised his price target on Valeant to $20, saying the company's "impressive" Q1 results demonstrate "good returns" on some of its strategic investments. Nachman also raised his FY18 EPS target to $3.42 from $3.12 to reflect the company's raised FY18 guidance. The analyst keeps his Market Perform rating amid continued uncertainty about sustainability of certain revenue drivers and potential contribution from its "key new product launches".
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/15/18
MZHO
05/15/18
UPGRADE
MZHO
Buy
Valeant upgraded to Buy from Neutral at Mizuho
TSLA Tesla
$283.21

-8.63 (-2.96%)

05/15/18
MSCO
05/15/18
NO CHANGE
Target $291
MSCO
Equal Weight
Tesla price target lowered to $291 from $376 at Morgan Stanley
Morgan Stanley analyst Adam Jonas made significant cuts to his near-term and long-term auto margin forecasts for Tesla following the company's Q1 report to reflect lingering manufacturing issues with the Model 3, which drove his price target on the stock down to $291 from $376. He has also delayed his forecast for the launch of Tesla's mobility-as-a-service network by roughly a year, to the middle of 2019, and increased his estimate for Tesla's capital raising to $3B from $2.5B. Jonas, who continues to expect Tesla will raise capital in the third quarter of this year, believes an added level of caution is prudent regarding Tesla and maintains an Equal Weight rating on the shares.
05/11/18
NOMU
05/11/18
NO CHANGE
Target $420
NOMU
Buy
Nomura lays out path to Tesla hitting $500 per share in two years
Nomura Instinet analyst Romit Shah believes the narrative on Tesla will shift over the next six months from insolvency risk and cash burn to market opportunity and growth. The analyst created a "Tesla Storyboard," which lays out the path to a $100B valuation, or $500 stock price, within two years. He keeps a Buy rating on Tesla with a $420 price target.
05/03/18
BARD
05/03/18
NO CHANGE
Target $411
BARD
Outperform
Tesla weakness a buying opportunity, says Baird
Baird analyst Ben Kallo said Tesla's Q1 results beat on all metrics and recommend investors ignore all the noise about Musk not answering several questions on the conference call. He said investors should focus on the company's progress and recommended buying the shares. The analyst said demand remains strong, the company lowered its capex estimates, and the company continues to execute on its strategy. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
05/03/18
GSCO
05/03/18
NO CHANGE
Target $195
GSCO
Sell
Tesla cash levels lower than anticipated, says Goldman Sachs
Goldman Sachs analyst David Tamberrino kept his Sell rating and $195 price target on Tesla after its "mixed" Q1 earnings, saying that while gross margins were better than expected, the company's cash levels were below his forecasts. The analyst also cites "sparse" details around the improvement for Tesla's Fremont manufacturing facility and points to the company's rising net debt levels.
VIPS Vipshop
$12.17

-2.93 (-19.40%)

05/15/18
LYON
05/15/18
DOWNGRADE
LYON
Underperform
Vipshop downgraded to Underperform from Buy at CLSA
02/13/18
02/13/18
UPGRADE
Target $20

Outperform
Vipshop upgraded to Outperform on improved growth prospects at Macquarie
As previously reported, Macquarie analyst Wendy Huang upgraded Vipshop (VIPS) to Outperform from Neutral following the company's revenue and earnings beat in Q4. Huang believes the company's recently announced tie-up with Tencent (TCEHY) and JD.com (JD) has strengthened its growth prospects, as it can accelerate user acquisitions and help the company attract more brands and better products to sell. Huang, who also reiterated JD.com as her top pick among e-commerce names, has a $20 price target on Vipshop shares.
02/13/18
02/13/18
UPGRADE
Target $20

Outperform
Follow-up: Vipshop upgraded to Outperform on growth prospects at Macquarie
As previously reported, Macquarie upgraded Vipshop to Outperform from Neutral following the Q4 beat and better than expected Q1 guidance. Analyst Wendy Huang raised Vipshop's price target to $20 from $9 and increased estimates due to stronger growth prospects Huang believes the tie-ups with Tencent and JD.com will drive accelerated user acquisitions, generate synergies in the logistics business, and enable Vipshop to attract more brands and better SKUs.
02/14/18
BNCH
02/14/18
NO CHANGE
Target $24
BNCH
Buy
Vipshop price target raised to $24 on 'milestone' partnership at Benchmark
Benchmark analyst Fawne Jiang raised her price target on Vipshop (VIPS) to $24 from $12, stating that its partnership with Tencent (TCEHY) and JD.com (JD) is a "milestone" step with both substantial financial benefits and the potential to unleash Vipshop's strategic value as an e-commerce asset. Jiang reiterated her Buy rating on Vipshop shares following the company's "solid" Q4 report.
A Agilent
$63.33

-5.91 (-8.54%)

05/15/18
BARD
05/15/18
NO CHANGE
Target $77
BARD
Outperform
Agilent core growth slowing, but underlying business healthy, says Baird
Baird analyst Catherine Ramsey Schulte said Agilent's Q2 growth hit the guidance midpoint, but fell short of expectations due to unforeseen headwinds in China and ICP/MS shipment timing. She noted management remains bullish on end-market outlooks and she still believes they are being conservative with guidance. Although the company's core growth is slowing, she said the underlying business is healthy. Schulte reiterated her Outperform rating and lowered her price target to $77 from $78 on Agilent shares.
04/09/18
04/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. General Motors (GM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he sees room for positive earnings revisions for GM, Ford (F) and Fiat Chrysler (FCAU) as investors better understand the impact on U.S. pick-up truck sales from a potential passage of a U.S. infrastructure bill. 2. TD Ameritrade (AMTD) upgraded to Buy from Neutral at BofA/Merrill with analyst Michael Carrier saying he views TD Ameritrade's near-term outlook as attractive given healthy new net asset growth, higher interest rates, and strong DARTs. 3. Comerica (CMA) upgraded to Outperform from Neutral at Wedbush with analyst Peter Winter saying he sees several levers that should drive above average earnings per share growth over the next two years, including margin expansion, potential resumption of loan growth, and above average capital returns. 4. Agilent (A) upgraded to Buy from Neutral at Goldman Sachs with analyst Patrick Donnelly saying he sees an attractive fundamental backdrop across Tools. 5. Discover (DFS) and Ally Financial (ALLY) were upgraded to Equal Weight from Underweight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/15/18
COWN
05/15/18
UPGRADE
COWN
Outperform
Agilent upgraded to Outperform from Market Perform at Cowen
05/15/18
JEFF
05/15/18
NO CHANGE
Target $80
JEFF
Buy
Agilent pullback a buying opportunity, says Jefferies
Jefferies analyst Brandon Couillard recommends using the post-earnings pullback in shares of Agilent Technologies as a buying opportunity. Guidance was maintained, despite dilution from Lasergen, and does not yet capture accretion from the pending AATI deal, Couillard tells investors in a research note. He sees no reason to alter his positive thesis and keeps a Buy rating on Agilent with a slightly reduced price target of $80.

TODAY'S FREE FLY STORIES

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

LNC

Lincoln National

$68.89

-0.555 (-0.80%)

16:24
05/25/18
05/25
16:24
05/25/18
16:24
Syndicate
Breaking Syndicate news story on Lincoln National »

Lincoln National files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGLY

Digital Ally

$2.63

0.075 (2.94%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Digital Ally »

Digital Ally files $25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNGX

Soligenix

$1.58

-0.005 (-0.32%)

16:23
05/25/18
05/25
16:23
05/25/18
16:23
Syndicate
Breaking Syndicate news story on Soligenix »

Soligenix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$35.34

0.08 (0.23%)

16:21
05/25/18
05/25
16:21
05/25/18
16:21
Hot Stocks
HFF Inc. announces $640M sale of 5 Bryant Park office tower in Manhattan »

HFF announces the $640M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
05/25/18
05/25
16:20
05/25/18
16:20
Options
Closing CBOE SPX and VIX Index summary for May 25th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMED

OncoMed

$2.81

0.06 (2.18%)

16:19
05/25/18
05/25
16:19
05/25/18
16:19
Syndicate
Breaking Syndicate news story on OncoMed »

OncoMed files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTEM

Molecular Templates

$7.02

0.34 (5.09%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Syndicate
Breaking Syndicate news story on Molecular Templates »

Molecular Templates files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
05/25/18
05/25
16:17
05/25/18
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

, USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 2.1K…

SPY

SPDR S&P 500 ETF Trust

$272.22

-0.65 (-0.24%)

USO

United States Oil Fund

$13.68

-0.605 (-4.24%)

GLD

SPDR Gold Trust

$123.21

-0.4 (-0.32%)

FXE

Euro Currency Trust

$111.98

-0.62 (-0.55%)

FXC

CurrencyShares Canadian Dollar Trust

$76.07

-0.37 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
05/25/18
05/25
16:16
05/25/18
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$102.20

0.1 (0.10%)

16:15
05/25/18
05/25
16:15
05/25/18
16:15
Periodicals
Disney cuts opening weekend sales forecast for 'Solo', Bloomberg says »

Disney cut its domestic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMSA

Fairmount Santrol

$5.51

-0.26 (-4.51%)

16:11
05/25/18
05/25
16:11
05/25/18
16:11
Hot Stocks
Fairmount Santrol, Unimin receive final merger approval »

Fairmount Santrol and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBL

RumbleON

$4.88

0.16 (3.39%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on RumbleON »

RumbleON files $20M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UAVS

Ageagle Aerial Systems

$2.25

0.04 (1.81%)

16:10
05/25/18
05/25
16:10
05/25/18
16:10
Syndicate
Breaking Syndicate news story on Ageagle Aerial Systems »

Ageagle Aerial Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARCI

Appliance Recycling

$0.82

(0.00%)

16:08
05/25/18
05/25
16:08
05/25/18
16:08
Hot Stocks
Appliance Recycling receives noncompliance notice from NASDAQ »

Appliance Recycling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CIT

CIT Group

$51.62

-1.13 (-2.14%)

16:06
05/25/18
05/25
16:06
05/25/18
16:06
Hot Stocks
CIT Group names Marisa Harney chief risk officer »

CIT Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.81

(0.00%)

16:04
05/25/18
05/25
16:04
05/25/18
16:04
Hot Stocks
Breaking Hot Stocks news story on Trivago »

Par Investment Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.